Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims: To build a flexible and comprehensive long‐term Type 1 diabetes mellitus model incorporating the most up‐to‐date methodologies to allow a number of cost‐effectiveness evaluations. Methods: This paper describes the conceptual modelling, model implementation and model validation of the Sheffield Type 1 Diabetes Policy Model (version 1.0), developed through funding by the UK National Institute for Health Research as part of the Dose Adjustment for Normal Eating research programme. The model is an individual patient‐level simulation model of Type 1 diabetes and it includes long‐term microvascular (retinopathy, neuropathy and nephropathy) and macrovascular (myocardial infarction, stroke, revascularization and angina) diabetes‐related complications and acute adverse events (severe hypoglycaemia and diabetic ketoacidosis). The occurrence of these diabetes‐related complications in the model is linked to simulated individual patient‐level risk factors, including HbA 1c, age, duration of diabetes, lipids and blood pressure. Transition probabilities were modelled based on a combination of existing risk functions, published trials, epidemiological studies and individual‐level data from the Dose Adjustment for Normal Eating research programme. Results: The model takes a lifetime perspective, estimating the impact of interventions on costs, clinical outcomes, survival and quality‐adjusted life years. Validation of the model suggested that, for almost all diabetes‐related complications predicted, event rates were within 10% of the normalized rates reported in the studies used to build the model. Conclusions: The model is highly flexible and has broad potential application to evaluate the Dose Adjustment for Normal Eating research programme, other structured diabetes education programmes and other interventions for Type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
Caro, J. J., Briggs, A. H., Siebert, U., & Kuntz, K. M. (2012) · Medical Decision Making · doi:10.1177/0272989x12454577 · Cited by 520
Cederholm, J., Eeg-Olofsson, K., Eliasson, B., Zethelius, B., Gudbjörnsdottir, S., & Register, O. B. O. T. S. N. D. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03342.x · Cited by 90
Cited by
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21200 · Cited by 73
Self-citationMcQueen, R. B., Breton, M. D., Ott, M., Koa, H., Beamer, B., & Campbell, J. D. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815599551 · Cited by 17
Abegaz, T. M., Diaby, V., Sherbeny, F., & Ali, A. A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01160-8 · Cited by 15
Roze, S., Isitt, J. J., Smith-Palmer, J., & Lynch, P. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s304395 · Cited by 15
Harris, S., Cimino, S., Nguyen, Y., Szafranski, K., & Poon, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01677-5 · Cited by 12
“…T1DM, complications are modeled using the Sheffield Type 1 Diabetes Model equations, which were primarily derived from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study and the Wisconsin Epidemiological Study of Diabetic Retinopathy [19–21].”
McQueen, R. B., Breton, M. D., Craig, J., Holmes, H., Whittington, M. D., Ott, M. A., & Campbell, J. D. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818769098 · Cited by 12
Metadata
- Authors
- Thokala, P., Kruger, J., Brennan, A., Basarir, H., Duenas, A., Pandor, A., Gillett, M., Elliott, J., & Heller, S.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2014-02-05
- Volume
- 31
- Issue
- 4
- Pages
- 477-486
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2055173561
- Cited by
- 39
- References
- 3
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.